Long-term Tolvaptan Treatment of Autosomal Dominant Polycystic Kidney Disease in Korea

Ha Yeon Kim1*, Seung Jin Lee2*, Byung Ki Kim3, Minah Kim1, Eun Hui Bae1, Seong Kwon Ma1, Soo Wan Kim1

1Department of Internal Medicine, Chonnam National University Medical School, Gwangju, 2Department of radiology, Chonnam National University Medical School, Gwangju, 3Department of Internal Medicine, Saint Carollo Hospital, Suncheon, Jeollanam-do, Korea

Received: December 4, 2018
Accepted: February 26, 2019
Corresponding Author: Soo Wan Kim, MD, PhD.
Department of Internal Medicine, Chonnam National University Medical School, 42 Jebongro, Gwangju 57218, Korea
Tel: +82-62-220-6271
Fax: +82-62-225-8578
E-mail: skimw@chonnam.ac.kr

The email address of all authors: Ha Yeon Kim, borome@hanmail.net; Seung Jin Lee, vet-lee@daum.net; Byung Ki Kim, azmime@naver.com; Minah Kim, karbiya@naver.com; Eun Hui Bae, baedak@hanmail.net; Seong Kwon Ma, drmsk@hanmail.net; Soo Wan Kim, skimw@chonnam.ac.kr
*These authors contributed equally.

A 22-year-old male patient was diagnosed with autosomal dominant polycystic kidney disease (ADPKD). He received conservative treatment with an angiotensin-converting enzyme inhibitor. Two years later, oral therapy, consisting of 60 mg tolvaptan per day, was initiated. Compared with height-adjusted total kidney volume, the rate of kidney growth reduced significantly from 7.33% to 0.66% annually, since commencement of the tolvaptan therapy. The liver enzyme profile and serum sodium level and osmolality were constantly within normal ranges. In Korea, this is the first reported case of a patient with ADPKD who received tolvaptan treatment for more than 1 year. This case demonstrates that long-term tolvaptan treatment appears to be safe, well tolerated, and effective for ADPKD.

Key Words: Autosomal dominant polycystic kidney disease, Tolvaptan, V2-antagonist, Long-term outcome

Introduction

Autosomal dominant polycystic kidney disease (ADPKD) is a common genetic disorder, but there are no effective treatments till date. Tolvaptan, a V2 receptor antagonist, is known to be beneficial in the inhibition of cystic growth in patients with ADPKD. Tolvaptan was approved as a treatment modality for ADPKD in Korea; however, its long-term use in clinical practice is rare because of its high cost. Herein, we describe a case of a 22-year-old male ADPKD patient who was treated with tolvaptan for 1 year.

Case Report

A 22-year-old male patient visited the renal department of Chonnam National University Hospital for evaluation of an abnormal computed tomography (CT) finding. His height was 179 cm, body weight was 58 kg, and body mass index was 18 kg/m². There was no history of any underlying disease and, at the time, he was not taking any medication. His family history was non-specific. Initial laboratory findings were all within normal range. Laboratory investigations showed leukocyte count, 9,500 cells/mL; hemoglobin, 13.0 g/dL; platelet count, 340,000 cells/mL; blood urea nitrogen level, 16.1 mg/dL; creatinine, 0.75 mg/dL; estimated glomerular filtration rate, 130.2 mL/min/1.73 m² (which was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula: mL/min/1.73 m²=141 × minimum (creatinine/k, 1) 1.209 × 0.993α × maximum (creatinine/k, 1) 1.159 (if black), where k is 0.7 for women and 0.9 for men, and a is −0.329 for women and −0.411 for men); sodium level, 138 mEq/L; potassium level, 4.0 mEq/L; chloride level, 114 mEq/L; magnesium level, 2.0 mg/dL;
Fig. 1. Abdominal computed tomography at January 2015, April 2017, and April 2018. A) Right kidney: length, 171.30 mm; width, 120.29 mm; depth, 65.80 mm. Left kidney: length, 163.42 mm; width, 101.88 mm; depth, 79.86 mm. B) Right kidney: length, 183.88 mm; width, 122.46 mm; depth, 70.25 mm. Left kidney: length, 170.62 mm; width, 102.77 mm; depth, 86.24 mm. C) Right kidney: length, 183.90 mm; width, 126.06 mm; depth, 68.77 mm. Left kidney: length, 164.02 mm; width, 106.24 mm; depth, 86.75 mm.

Contrast-enhanced CT of the abdomen (Fig. 1A) was performed. Over 20 cysts were detected in both kidneys and in the liver. The right kidney size was 171.30 mm (length) × 120.29 mm (width) × 65.80 mm (depth), and the left kidney size was 163.42 mm (length) × 101.88 mm (width) × 79.86 mm (depth).

Genetic analysis was performed using Sanger’s method. Direct sequencing revealed that the 22nd intron had translocated from G to A, which was previously reported as a pathogenic variant, but the change in amino acid was unknown (Fig. 2)\(^2\).

An angiotensin-converting enzyme inhibitor treatment was started and a follow-up CT was performed after 2 years (Fig. 1B). The volume of each kidney was as follows: right kidney volume, 828 mL; left kidney volume, 791 mL; total kidney volume (TKV), 1,620 mL; and height-adjusted total kidney volume (HtTKV), 905 mL/m. The CT showed that the growth rate of the HtTKV was 7.33% per year.

From May 2017, tolvaptan therapy was initiated at a dose of 60 mg per day, with morning and afternoon doses at 45 mg and 15 mg, respectively. Monthly checks of the body weight, blood pressure, and laboratory tests including complete blood count, renal function test, electrolyte test, liver function test, random urine electrolytes, and osmolality were performed. Further clinical course was uneventful and the electrolyte levels remained unremarkable. The patient did not report any specific side effects of the tolvaptan therapy, except polyuria and polydipsia. The liver enzyme profile and serum sodium level and osmolality remained within normal range. The serum creatinine was 0.97 mg/dL after 1 year of the tolvaptan therapy (Fig. 3). The urine osmolality decreased to less than 300 mOsmol/kg and urine sodium was less than 100 mOsmol/kg.

Another follow-up abdominal CT was performed 11 months after commencement of tolvaptan therapy (Fig. 1C). The size of each kidney was as follows: right kidney volume, 837 mL; left kidney volume, 792 mL; TKV, 1,629 mL; and HtTKV, 910 mL/m. The growth rate of HtTKV decreased from 7.33% to 0.66% (Fig. 4). Till the foreseeable future, the plan is to maintain the current tolvaptan therapy with its same dosage, unless a specific problem occurs.
Fig. 3. Course of serum creatinine levels (line) and estimated glomerular filtration rate (bar) during tolvaptan treatment. From May 2017, tolvaptan was initiated at a daily dose of 60 mg.

Fig. 4. Comparing the total kidney volume before and after tolvaptan therapy; the cyst growth rate decreased from 7.33% to 0.66%.

Discussion

ADPKD is a genetic disorder characterized by the growth of multiple, variable-sized cysts in the kidneys. ADPKD is often accompanied by abnormalities in two major intracellular messengers: calcium and 3',5'-cyclic adenosine monophosphate (cAMP). Proteins polycystin 1 and polycystin 2 regulate intracellular calcium levels, and intracellular calcium plays a role in inhibiting cyclic AMP; increased cAMP plays a significant role in cyst growth3-5). In addition, adenylyl cyclase 6 regulates inner medullary cAMP formation and aquaporin-2 phosphorylation and expression. Vasopressin V2 receptor (V2R) mediates the activation of adenylyl cyclase 6 and cAMP-enhanced phosphorylation of aquaporin-26). Therefore, a V2 receptor antagonist inhibits the progression of ADPKD by reducing intracellular cAMP and adenylyl cyclase 6. The TEMPO clinical trial7) and the recent REPRISE clinical trial7) demonstrated higher impediment of cyst growth and preservation of the estimated glomerular filtration rate in the tolvaptan-treated group than in the control group. Because of the risk of liver-enzyme level elevation, this clinical trial suggested that a regular checkup of liver function is required.

In our case, tolvaptan was administered at 60 mg per day for about 1 year. After taking tolvaptan for the first time, the patient complained of aquaresis-related symptoms such as polyuria (>5 L) and polydipsia but his weight remained constant. There were no specific side effects including elevation of liver-enzyme levels.

Abdominal CT was performed 3 times: at baseline, 2 years after conservative treatment, and 11 months after commencement of tolvaptan therapy. The TKV indicates the progression of renal insufficiency in patients with ADPKD; thus, qualifying it as a predictive biomarker is important9,10). The radiologist in Chonnam National University Hospital measured the kidney’s width, depth, and length each time. The TKV was measured using the ellipsoid method and adjusted with the height10). When
comparing the TKV before and after tolvaptan therapy, it is seen that the cyst growth rate decreased from 7.33% to 0.66%, and this suggests that the tolvaptan treatment was effective in slowing cyst growth.

**Conclusion**

We conclude that tolvaptan has been shown to reduce the growth rate of kidney cysts in this patient with ADPKD who received tolvaptan treatment for 1 year.

**Competing interests**

The authors state that they have no competing interests.

**Acknowledgement**

This research was assisted by two grants from Chonnam National University Hospital Biomedical Research Institute (CRI18015-1 & CRI16015-1).

**References**

1. Levey AS, Stevens LA, Schnidt CH, et al.: A new equation to estimate glomerular filtration rate. Annals of internal medicine 150:604-612, 2009
2. Gabow PA: Autosomal dominant polycystic kidney disease. Am J Kidney Dis 22:511-512, 1993
3. Gattone VH, 2nd, Wang X, Harris PC, Torres VE: Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9:1323-1326, 2003
4. Gabow PA: Autosomal dominant polycystic kidney disease. N Engl J Med 329:332-342, 1993
5. Torres VE, Harris PC, Pirson Y: Autosomal dominant polycystic kidney disease. Lancet 369:1287-1301, 2007
6. Rieg T, Tang T, Murray F, et al.: Adenylate cyclase 6 determines cAMP formation and aquaporin-2 phosphorylation and trafficking in inner medulla. J Am Soc Nephrol 21:2059-2068, 2010
7. Torres VE, Chapman AB, Devuyst O, et al.: Investigators: Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367:2407-2418, 2012
8. Torres VE, Chapman AB, Devuyst O, et al.: Investigators: Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. N Engl J Med 377:1930-1942, 2017
9. Grantham JJ, Torres VE, Chapman AB, et al.: Investigators: Volume progression in polycystic kidney disease. N Engl J Med 354:2122-2130, 2006
10. Chapman AB, Bost JE, Torres VE, et al.: Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 7: 479-486, 2012